Tokyo, March 8 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000060845) titled 'Assessment of QUAlity of eye-RElated Life and vision in subjects using single-use vision-correcting soft contact LEns wear' on March 6.

Study Type: Observational

Primary Sponsor: Institute - Kozaki eye clinic

Condition: Condition - Myopia Classification by malignancy - Others Genomic information - NO

Objective: Narrative objectives1 - This study aims to explore the efficacy and safety of switching patients from other daily disposable hydrogel contact lenses to Bausch+ Lomb Aqualox 1-Day UVSHIN. Basic objectives2 - Safety,Efficacy

Eligibility: Age-lower limit - 18 years-old <= Age-upper limit - Not applicable Gender - Male and Female Key inclusion criteria - 1.Individuals aged 18 years or older at the time of consent acquisition. 2.Individuals who, prior to prescription of the study product, had used identical daily disposable hydrogel soft contact lenses (other products) in both eyes for at least 3 months, wearing them at least 4 days per week for 8 hours or more per day. 3.Individuals who are already using the study product in both eyes. 4.Individuals with a cylinder power of less than 1.25D in the fully corrected refractive error during the subjective refraction test at the time of prescribing the study product. 5.Individuals achieving a corrected distance visual acuity of 0.7 or better in one eye with the study product. 6.Individuals who understand the purpose of this study and have personally signed the consent form for participation. Key exclusion criteria - 1.Individuals with systemic diseases or ocular diseases (cataracts, glaucoma, macular diseases) that may affect the results, or those with a history of eye surgery (including laser surgery). 2.Individuals who used hard contact lenses within 30 days prior to starting use of the study product. 3.Individuals who used multiple products within 3 months prior to starting use of the study product. 4.Individuals who have used the study product for 30 days or more. 5.Individuals using eye drops for the purpose of alleviating or treating hay fever symptoms. 6.Individuals with a conflict of interest with this study or the research institution. 7.Individuals requiring a proxy decision-maker. 8.Other individuals deemed unsuitable for study participation by the investigator or others. Target Size - 60

Recruitment Status: Recruitment status - Completed Date of protocol fixation - 2023 Year 12 Month 06 Day Date of IRB - 2023 Year 12 Month 19 Day Anticipated trial start date - 2024 Year 05 Month 17 Day Last follow-up date - 2025 Year 04 Month 05 Day

To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000069622

Disclaimer: Curated by HT Syndication.